SCHEMBL1602250

SCHEMBL1602250

COc1ccc(S(=O)(=O)N(Cc2ccccc2)[C@H](NC(=O)O)[C@@H](C)O)cc1CC(C)CCC#N

nearest known ligand 0.40

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
TAS2R14 Q9NYV8 4/20 0.39
BMP1 P13497 1/20 0.39
PDE4A P27815 1/20 0.39
PDE4B Q07343 1/20 0.39
PDE4C Q08493 1/20 0.39
PDE4D Q08499 1/20 0.39
KMT2A Q03164 1/20 0.38
ALDH1A1 P00352 3/20 0.38
GAA P10253 1/20 0.38
MAPT P10636 2/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
TP53 P04637 1/20 0.37
HTT P42858 2/20 0.37
THRB P10828 1/20 0.37
KEAP1 Q14145 2/20 0.36
NFE2L2 Q16236 1/20 0.36
LMNA P02545 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1601954 0.91 KMT2A (0.38) TAS2R14BMP1PDE4APDE4BPDE4C
SCHEMBL1602654 0.89 PDE4A (0.40) TAS2R14BMP1PDE4APDE4BPDE4C
SCHEMBL1602738 0.86 BMP1 (0.38) TAS2R14BMP1PDE4APDE4BPDE4C
SCHEMBL1601501 0.86 BMP1 (0.38) TAS2R14BMP1PDE4APDE4BPDE4C
SCHEMBL1601216 0.84 KMT2A (0.36) TAS2R14BMP1PDE4APDE4BPDE4C
SCHEMBL1601957 0.79 TP53 (0.39) TAS2R14KMT2AALDH1A1GAAMAPT
SCHEMBL1602478 0.78 ALDH1A1 (0.38) TAS2R14KMT2AALDH1A1GAAMAPT
SCHEMBL5103867 0.77 ALDH1A1 (0.38) TAS2R14BMP1KMT2AALDH1A1GAA
SCHEMBL1602814 0.76 TP53 (0.39) TAS2R14KMT2AALDH1A1MAPTSMN1; SMN2
SCHEMBL1602845 0.76 KMT2A (0.38) TAS2R14KMT2AALDH1A1MAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7919523-B2 Inhibitors of aspartyl protease VERTEX PHARMACEUTICALS, INC. (US) 2011-04-05 US disclosed
US-20090042973-A1 Inhibitors of aspartyl protease VERTEX PHARMACEUTICALS INCORPORATED 2009-02-12 US disclosed
US-7442718-B2 Inhibitors of aspartyl protease VERTEX PHARMACEUTICALS INCORPORATED (US) 2008-10-28 US disclosed
EP-1637518-A2 Inhibitors of aspartyl protease Vertex Pharmaceuticals Incorporated (US) 2006-03-22 EP disclosed
US-20040127488-A1 Inhibitors of aspartyl protease VERTEX PHARMACEUTICALS INCORPORATED 2004-07-01 US disclosed
US-6617350-B2 Sulfonamides which are aspartyl protease inhibitors; well suited for inhibiting HIV-1 and HIV-2 protease activity VERTEX PHARMACEUTICALS INCORPORATED 2003-09-09 US disclosed
US-20020198388-A1 Inhibitors of aspartyl protease VERTEX PHARMACEUTICALS INCORPORATED 2002-12-26 US disclosed
US-6319946-B1 BENZODIOXOLYLSULFONAMIDES; INHIBITING HIV-1 AND HIV-2 PROTEASE ACTIVITY VERTEX PHARMACEUTICALS INCORPORATED 2001-11-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090042973-A1 Inhibitors of aspartyl protease SPINT2, DNPEP, PRSS1 TAS2R14 2211/4885BMP1 4692/4885PDE4A 3727/4885
US-20040127488-A1 Inhibitors of aspartyl protease SPINT2, DNPEP, PRSS1 TAS2R14 2211/4885BMP1 4692/4885PDE4A 3727/4885
US-20020198388-A1 Inhibitors of aspartyl protease SPINT2, DNPEP, PRSS1 TAS2R14 2211/4885BMP1 4692/4885PDE4A 3727/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.